To obtain the subject preparation that can make the progress of maculopathy and macular degeneration slow down, or can stop it, if possible, by using a specific alkanoyl L-carnitine as an active ingredient.

The objective preparation is obtained by using an alkanoyl L-carnitine where the alkanoyl has 2-6 carbon atoms and pharmacologically acceptable salt. The alkanoyl L-carnitine is selected, for example, from acetyl, propionyl, valeryl and isovarelyl L-carnitines. The pharmacologically acceptable salt is selected, for example, from chloride, bromide, orotate (and ester). This preparation is used for prevention and treatment of age-dependent maculopathy(ARM), age-independent maculopathy (nARM) and diabetic retinopathy, the treatment of neuroretinopathy and age-dependent macular degeneration(AMD). This preparation can orally or parenterally given to the patients afflicted with ARM, nARM and AMD.